Objective-Aortic aneurysm, focal dilation of the aorta, results from impaired integrity of aortic extracellular matrix (ECM).
A mong aortic diseases, aortic aneurysm is a great health concern with fatal or devastating outcomes. It is often asymptomatic until it ruptures causing significant morbidities and >80% mortality. [1] [2] [3] It is the 15th most common cause of death in the Western world. 4 Pharmacological treatments, such as β-blockers, 5, 6 angiotensin II (Ang II) receptor blockers, 6, 7 Ang II-converting enzyme inhibitors, 6, 8, 9 and statins, 10, 11 have not shown consistent and significant improvements in clinical outcomes. Surgical repair can stabilize large aneurysms but are often limited to cases where the risk of rupture exceeds that of the surgical intervention, 12 and even then subsequent mortality and morbidity remain high. [13] [14] [15] Therefore, better understanding of the molecular mechanism responsible for development and progression of aortic aneurysm may be necessary in developing effective treatments for this devastating disease.
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Weakened aortic wall and compromised integrity of the extracellular matrix (ECM) are among the common features in different types of aortic aneurysm. The predominant ECM structural proteins in the aorta are elastin that provides the recoil property of the aortic wall and collagen that provides the tensile strength to withstand the high blood pressure during cardiac systole. Physiological turnover of the aortic ECM includes degradation of its existing proteins by matrix metalloproteinases (MMPs) 16 to be replaced by newly synthesized proteins. Activity of MMPs is tightly regulated by their physiological inhibitors, tissue inhibitor of metalloproteinases. Among MMPs, MMP2 is capable of degrading multiple ECM components, including collagen and elastin, 16, 17 and has been strongly linked to excess ECM degradation in aneurysmal aorta as its levels are elevated in thoracic and abdominal aortic aneurysms (AAAs). [18] [19] [20] [21] [22] [23] [24] MMP2-deficient mice are protected against AAA in a model of adventitial CaCl 2 exposure 25 ; however the role of MMP2 in thoracic aortic aneurysm (TAA) has not yet been explored. Thoracic aorta consists of greater elastin lamellae layers and a greater elastin:collagen ratio that reverses in the abdominal aorta. 26, 27 Given the differential ECM composition and histological characteristics of the thoracic versus abdominal aorta, 15 MMP2 could play regionally distinct roles in remodeling of the aorta.
In this study, we used 2 experimental models of aortic remodeling and aneurysm, Ang II infusion that triggers ECM synthesis, as well as degradation, and adventitial CaCl 2 exposure that only triggers ECM degradation. Ang II is a physiological hormone elevated in patients with cardiovascular diseases, [28] [29] [30] which leads to vascular remodeling, 31 whereas adventitial CaCl 2 exposure is an established experimental model of aortic aneurysm in rodents 32, 33 and in large mammals. 34 The findings in this study reveal a dual function of MMP2 in ECM synthesis, as well as degradation, and differential susceptibility of the thoracic and abdominal aorta to reduced synthesis versus excess proteolysis of ECM proteins.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Experimental Animals and Procedures
Wild-type (WT; The Jackson Laboratory) and MMP2-deficient (MMP2 −/− ) 35 mice in C57BL/6 background received Ang II (SigmaAldrich) [36] [37] [38] or saline (control) for 4 weeks. Systolic blood pressure was measured using the tail-cuff method (iiTC Life Science, Woodland Hills, CA) as before. 39 TAA by CaCl 2 exposure was induced in WT and MMP2 −/− mice as described. 32, 40 All animal experiments were performed in accordance with Canadian Council on Animal Care Guidelines and regulations of Animal Policy and Welfare committee at the University of Alberta.
Statistical Analyses
Two-way ANOVA was performed to compare data sets with 2 main factors (genotype and treatment). Statistical analyses were performed using SPSS software (Version 10.1; Chicago, IL). Normality test (Shapiro-Wilk) was performed to confirm normal distribution of all data sets. Averaged values are presented as mean±SEM. Statistical significance was recognized at P<0.05.
Results

Ang II Infusion Led to Formation of TAA in MMP2 −/− Mice but Not in WT Mice
After 4 weeks of Ang II infusion, uniform remodeling was detected throughout the aorta in WT mice, whereas a striking aneurysmal dilation was detected in the thoracic aorta in MMP2 −/− mice ( Figure 1A ). AAA was not detected in either genotype ( Figure I in the online-only Data Supplement). Representative ultrasonic images ( Figure 1B) , averaged internal aortic diameter of ascending aorta ( Figure 1C ), the arch ( Figure 1D ), and the internal (i) and maximal external diameter (ii) of descending thoracic aorta ( Figure 1E) show that although aortic dilation was detected in WT-Ang-II, it was markedly greater in MMP2 −/− -Ang II group. We used these 2 measurements to document aortic dilation because accurate measurement of the inner aortic diameter using trichromestained sections can be challenging and influenced by the steps involved in tissue processing; therefore, inclusion of the maximal outer diameter is required to confirm aortic dilation. Baseline aortic diameters in saline-infused groups were comparable between the genotypes. Interestingly, the aortic arch diameter during cardiac systole (maximum diameter) was increased similarly between WT-Ang II and MMP2 −/− -Ang II mice (Figure 1Di ), whereas aortic diameter during cardiac diastole (minimum diameter) was significantly greater in MMP2 −/− -Ang II compared with WT-Ang II mice (Figure 1Dii To investigate the Ang II-induced molecular events underlying the marked structural disruption in the MMP2 −/− aortic wall, we measured the protein levels for elastin and collagen, the 2 main ECM structural proteins. Western blot analysis showed that Ang II infusion increased elastin and collagen protein levels in WT but not in MMP2 −/− thoracic aorta (Figure 3Ai and 3Aii). To determine whether the lower levels of elastin and collagen type I in MMP2 −/− -Ang II aorta are because of reduced synthesis or increased degradation, we first measured the mRNA levels for these molecules. In WT mice, Ang II infusion increased the elastin and collagen type I mRNA levels by 4-fold and 5-fold, respectively, whereas in the MMP2 −/− group, the Ang II-induced increase in these mRNAs was markedly suppressed (Figure 3Bi and 3Bii) . Next, we investigated how the lack of MMP2 altered the proteolytic activities in the thoracic aorta. Gelatin zymography showed increased pro-MMP2 (72 kDa) and active MMP2 levels (64 kDa) in WT-Ang II compared with WT-saline aortas and confirmed the lack of MMP2 in the aortas from MMP2-deficient mice (Figure 4Ai-4Aiii) . Consistently, mRNA levels of MMP2 were elevated only in WT-Ang II aortas (Figure 4Bi ), whereas MMP9 mRNA remained comparable among all groups (Figure 4Bii ). Ang II infusion did not alter In the abdominal aorta, the protein levels for elastin and collagen were comparable in Ang II-infused mice of either genotype despite the markedly reduced mRNA levels in MMP2 Collectively, these data indicate that the lack of MMP2 results in reduced production of elastin and collagen in the thoracic and abdominal aorta. However, in the abdominal aorta, the suppressed proteolytic activity is sufficient to sustain the protein content for elastin and collagen, whereas in the thoracic aorta, these ECM proteins are more predominantly dependent on their synthesis.
Impaired Activation of Latent Transforming Growth Factor-β and the Smad2/3 Pathway in MMP2-Deficient Aortas
To determine the underlying molecular mechanism for the impaired elastin and collagen synthesis in MMP2 −/− -Ang II mice, we examined the transforming growth factor-β1 (TGFβ1) signaling pathway, a well-known growth factor and cytokine that mediates the synthesis of ECM structural proteins. Activation of TGFβ requires its proteolytic release from its latent complex (latent-TGFβ-binding protein [LTBP]-TGFβ). We found that the Ang II-induced rise in active (25 kDa) TGFβ1 was significantly reduced in MMP2 −/− compared with WT aortas (Figure 5Ai and 5Aii) , and consistently, activation of the downstream Smad2/3 pathway was suppressed in MMP2 −/− -Ang II aortas as evident by reduced phosphoSmad2/3 levels and the phospho:total Smad2/3 ratio in this group (Figure 5Bi 
MMP2-Deficiency Is Protective Against CaCl 2 -Induced TAA
To further establish that MMP2 plays a divergent role in ECM homeostasis by contributing to both production and degradation of the ECM proteins, we used the well-established CaCl 2 exposure model that induces TAA primarily through promoting ECM degradation. A, Representative western blots (i) and averaged protein quantification for elastin (ii) and collagen type 1 (iii) in the thoracic aorta from the indicated groups. Coomassie blue-stained gel served as loading control; n=6 per group per genotype. B, Averaged mRNA levels for elastin (i) and collagen (ii) in the thoracic aorta from indicated groups; n=8 per group per genotype. *P<0.05 compared with corresponding saline group. §P<0.05 compared with wild-type (WT)-Ang II group. A.U. indicates arbitrary units; HPRT, hypoxanthine-guanine phosphoribosyltransferase; and R.E., relative expression. Supplement) and elevated MMP2 mRNA synthesis ( Figure  IVB in the online-only Data Supplement). After 6 weeks of adventitial CaCl 2 exposure, all WT mice (n=16) developed TAA, whereas none of the MMP2 −/− mice (n=14) exhibited dilation of the thoracic aorta ( Figure 6A ), while neither genotype exhibited aortic rupture. Histological analysis of the thoracic aortas confirmed lumenal dilation, structural degradation, interrupted elastin fibers in the medial layer, and adventitial fibrosis in WT but not in MMP2 −/− mice (Figure 6Bi and  6Bii) . Measurement of the internal diameter (i) and maximal external diameter (ii) of the descending thoracic aorta further confirmed the presence of aneurysmal dilation only in WT but not in MMP2 −/− mice ( Figure 6C ). Consistent with the degradation of the medial ECM in the WT-CaCl 2 group, elastase activity was significantly elevated in WT but not in MMP2 −/− aortas ( Figure 6D ). CaCl 2 treatment did not alter the mRNA expression levels of elastin nor collagen in either genotype (Figure 6Ei and 6Bii) . Therefore, the CaCl 2 -induced aortic aneurysm is primarily driven by excess degradation of the ECM (without enhanced synthesis), and the absence of the proteolytic function of MMP2 offers a protective effect against aneurysm formation in this model.
Discussion
Aortic aneurysm is the outcome of maladaptive remodeling of vascular ECM. MMPs, particularly MMP2, are best known as ECM-degrading enzymes, and as such, they are often associated with adverse outcomes in vascular pathologies. 20, 21, 41 In this study, we demonstrate 2 opposing roles for MMP2 in aortic wall remodeling whereby it contributes to production in addition to degradation of the ECM structural proteins. Ang II is a peptide hormone upregulated in several cardiovascular diseases and can trigger a range of cellular responses, including synthesis of ECM proteins, as well as enhanced proteolytic activities through activation of MMPs, such as MMP2. 15, 42, 43 Adventitial CaCl 2 exposure is an established model of thoracic 32, 33 and AAAs, 44 and as we and others have shown, is associated with early activation of MMP2 and aberrant ECM degradation. 44, 45 By using these 2 distinct models of aortic remodeling and aneurysm, we studied the comparative role of MMP2 in constructive versus destructive remodeling of the aortic ECM. Here, we report that in addition to serving as a potent ECM protease, MMP2 is a key factor for optimal ECM synthesis in the aortic wall through activation of latent TGFβ1 and the downstream Smad2/3 pathway.
Ang II promotes constructive ECM turnover by triggering proteolysis of the existing ECM proteins and de novo synthesis of ECM proteins to replace the degraded proteins. In the absence of MMP2, although the Ang II-mediated proteolysis is reduced, the suppressed production of elastin and collagen leaves the need for replenishment of degraded ECM components unmet, leading to adverse ECM remodeling and aortic aneurysm. The presence of TAA but not AAA in MMP2 −/− -Ang II mice, despite similar reductions in mRNA synthesis of elastin and collagen in both regions, could be because the suppressed Ang II-induced proteolysis in the absence of MMP2 is sufficient to preserve the elastin and collagen protein contents in the abdominal aorta, whereas in the thoracic aorta, the ECM integrity is more adversely affected by the reduced production of these proteins. This could reflect a differential ECM turnover rate in thoracic versus abdominal aorta. Thoracic and abdominal aortas have different characteristics that alter their susceptibility to different pathological stimuli. 15, 46, 47 For instance, although the wall thickness-to-lumen size is consistent throughout the aorta, the thoracic aortic wall consists of a greater number of elastin lamellae, whereas in the abdominal aorta, the elastin lamellae are comprised of a thicker layer of SMCs. Based on the higher content of elastin in the thoracic aorta, this region could be more susceptible to defects in ECM synthesis, whereas the abdominal aorta would be more vulnerable to excess ECM degradation. We have reported that Ang II infusion resulted in AAA (but not TAA) in mice lacking tissue inhibitor of metalloproteinase-3, a potent MMP inhibitor, because of increased proteolytic degradation and despite uninterrupted synthesis of ECM proteins. 48 Similarly, the lack of tissue inhibitor of metalloproteinase-1 49 or tissue inhibitor of metalloproteinase-2 44 exacerbated aortic dilation in different models of AAA. It is also plausible that the turnover rate for the ECM proteins in abdominal aorta is lower than that in the thoracic region, and therefore, as long as the existing ECM structure is preserved (by reduced proteolysis), the abdominal aorta would not be affected by reduced ECM synthesis. Notably, genetic disorders that interfere with collagen or elastin production or assembly are often associated with TAA and less frequently with AAA. 24 This differential susceptibility of the abdominal aorta to excess proteolysis could also suggest potential therapeutic advantages for reducing MMP activities in patients with AAA by MMP inhibitors, such as doxycycline, although recent reports have been contradictory. 50, 51 TGFβ is a multifunctional cytokine and growth factor contributing to several diseases, 52 and therefore, its activation is tightly regulated and involves many steps. TGFβ isoforms are transcribed with the latency-associated proprotein forming the small latent complex that is secreted as the large latent complex covalently bound to LTBP via a disulphide bond. After secretion, latent TGFβ (LTBP-TGFβ) is sequestered in the ECM through covalent binding of LTBPs to ECM proteins, such as fibrillin-1 (FBN1). TGFβ activation requires the release of the 25-kDa homodimer from the latent complex. Proteolytic cleavage of LTBP1 from the ECM and the subsequent release of TGFβ1 from the latency-associated proprotein complex yield bioavailability of TGFβ, activation of its receptors, the downstream Smad2/3 signaling pathway, and subsequent transcriptional regulation of matrix-associated proteins, such as elastin and collagen. [53] [54] [55] Among MMPs, MMP2, MMP9, and membrane type 1 MMP have been reported to be able to cleave and activate the latent TGFβ. [56] [57] [58] [59] In our study, Ang II infusion did not alter MMP9 levels in the aorta, whereas the increase in membrane type 1-MMP was comparable in WT and MMP2 −/− aortas, hence indicating a key role of MMP2 that was elevated in Ang II-infused WT aortas but absent in the MMP2 −/− mice. TGFβ can also trigger noncanonical, Smad-independent, signaling pathways, such as the mitogen-activated protein kinase pathways. 60, 61 We assessed the activation of the extracellular signal-regulated protein kinase and c-Jun N-terminal kinase pathways, determined by phosphorylation of extracellular signal-regulated protein kinase 1/2 and c-Jun N-terminal kinase 1/2, and did not find a significant Ang II-induced activation in either genotype (data not shown).
It is critical to note that the TAA observed in MMP2
−/− -Ang II mice is mediated by a distinct molecular mechanism from that identified in Marfan syndrome-associated TAA. [62] [63] [64] [65] The primary cause of TAA in Marfan syndrome is a mutation or loss of FBN1, the building unit of microfibrils that form the scaffold for elastin assembly. FBN1 is also one of the main ECM proteins to which LTBP binds to sequester latent TGFβ in the ECM. With loss of FBN1, as it occurs in the Fbn +/− mouse model of Marfan syndrome, sequestration of latent TGFβ in the ECM is compromised leading to increased bioavailability of TGFβ and therefore enhanced activation of the TGFβ-mediated pathways. 66 This is clearly the opposite scenario to our findings in MMP2 −/− mice where the lack of MMP2 hinders the release of ECM-bound latent TGFβ and therefore reduces its bioavailability and the subsequent ECM production. This could also explain the protective effects of MMP2-deficiency in FBN1 +/− mice that exhibited excess active TGFβ (and reduced latent TGFβ) levels. 67 The heterozygous loss of FBN1 (≈50%) in these mice would result in a reduced fraction of TGFβ that would exist in the latent form (FBN1-bound). Therefore, loss of MMP2 in these mice would prevent the proteolytic release of the remaining FBN1-bound latent TGFβ molecules, thereby controlling the otherwise overactivated TGFβ pathway resulting in improved outcomes. Our findings are consistent with an earlier study that reported interruption of the TGFβ pathway, through a loss-of-function mutation of TGFβ2, led to TAA formation in patients and in animal models. 68 Interestingly, mutations in TGFβ receptors also led to TAA but through increased TGFβ-mediated Smad pathway and increased collagen production, 47, 69 indicating that TGFβ can interact with multiple receptors to mediate its effects. Therefore, excess bioavailability or suppressed activation of TGFβ can lead to impaired ECM turnover and thereby enhanced susceptibility to TAA.
In conclusion, this study demonstrates an intriguing dual role of MMP2 in vascular ECM turnover where it is a key factor in mediating ECM synthesis in addition to ECM degradation. This further highlights the complexity of the function of MMPs, which extends well beyond their classically known ECM-degrading role. Furthermore, the regional susceptibility of the aorta to aneurysm could be partly explained by the greater susceptibility of the thoracic aorta to interruptions of ECM synthesis, whereas pathologies associated with excess ECM degradation would render the abdominal aorta susceptible to aneurysm formation. −/− mice (ii) after 6 weeks of CaCl 2 exposure. Arrows point to areas of CaCl 2 exposure. B, Trichrome, Verhoeff van Gieson (VVG), and picrosirius red (PSR) staining of the thoracic aorta of WT (i) and MMP2-deficient (ii) mice are shown in (A). C, Inner diameter measured from trichrome-stained cross-sections (i) and maximal outer diameter measured from whole aorta ex vivo (ii) in descending thoracic aorta in the indicated groups measured ex vivo in perfusefixed aortas (n=7 per group per genotype). D, Total elastase activity in the descending thoracic aorta of indicated groups (n=5 per group per genotype). E, mRNA levels of collagen type I (i) and elastin (ii) in the descending aorta of the indicated groups (n=5-7 per group per genotype). *P<0.05 vs corresponding saline group. §P<0.05 vs WT-CaCl 2 . HPRT indicates hypoxanthine-guanine phosphoribosyltransferase.
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